KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Current Deferred Revenue (2017 - 2025)

Historic Current Deferred Revenue for Co-Diagnostics (CODX) over the last 8 years, with Q3 2025 value amounting to $45557.0.

  • Co-Diagnostics' Current Deferred Revenue fell 2467.05% to $45557.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $45557.0, marking a year-over-year decrease of 2467.05%. This contributed to the annual value of $40857.0 for FY2024, which is 8872.75% down from last year.
  • Latest data reveals that Co-Diagnostics reported Current Deferred Revenue of $45557.0 as of Q3 2025, which was down 2467.05% from $45857.0 recorded in Q2 2025.
  • In the past 5 years, Co-Diagnostics' Current Deferred Revenue registered a high of $362449.0 during Q4 2023, and its lowest value of $18120.0 during Q1 2023.
  • Moreover, its 4-year median value for Current Deferred Revenue was $158791.0 (2021), whereas its average is $160704.0.
  • Within the past 5 years, the most significant YoY rise in Co-Diagnostics' Current Deferred Revenue was 159137.42% (2024), while the steepest drop was 8872.75% (2024).
  • Over the past 4 years, Co-Diagnostics' Current Deferred Revenue (Quarter) stood at $150000.0 in 2021, then surged by 141.63% to $362449.0 in 2023, then tumbled by 88.73% to $40857.0 in 2024, then increased by 11.5% to $45557.0 in 2025.
  • Its Current Deferred Revenue was $45557.0 in Q3 2025, compared to $45857.0 in Q2 2025 and $40857.0 in Q1 2025.